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ABSTRACT: Within mammals, there are often several functionally related glycoside hydrolases, which makes monitoring their
activities problematic. This problem is particularly acute for the enzyme β-glucocerebrosidase (GCase), the malfunction of which is a
key driver of Gaucher’s disease (GD) and a major risk factor for Parkinson’s disease (PD). Humans harbor two other functionally
related β-glucosidases known as GBA2 and GBA3, and the currently used fluorogenic substrates are not selective, which has driven
the use of complicated subtractive assays involving the use of detergents and inhibitors. Here we describe the preparation of
fluorogenic substrates based on the widely used nonselective substrate resorufin β-D-glucopyranoside. Using recombinant enzymes,
we show that these substrates are highly selective for GCase. We also demonstrate their value through the analysis of GCase activity
in brain tissue homogenates from transgenic mice expressing mutant human GCase and patient fibroblasts expressing mutant GCase.
This approach simplifies the analysis of cell and tissue homogenates and should facilitate the analysis of clinical and laboratory tissues
and samples.
■ INTRODUCTION
β-Glucocerebrosidase (GCase) is a member of lysosomal
glycoside hydrolase family 30 (GH30)1 encoded by the gene
GBA and is responsible for the hydrolysis of the glycosidic
linkage of the glycolipid glucosylceramide. Homozygous loss of
function mutations in the GBA gene cause the lysosomal
storage disease known as Gaucher’s disease (GD),2 which
shows high variability in presentation and sometimes manifests
neuronopathic symptoms.3 Heterozygous loss of function
mutations in GBA are the greatest genetic risk factor for the
development of Parkinson’s disease (PD).4 Reduced GCase
activity correlates with increased aggregation of the protein α-
synuclein, which forms the toxic fibrils that are a pathological
hallmark of PD.5 Encouraging preclinical data from transgenic
PD model mice have demonstrated that increasing GCase
activity hinders the progression of PD.6−8 Furthermore, GCase
modulators that enhance activity may reduce the extent of α-
synuclein aggregation in patient cell lines.9,10 The robust data
in the literature demonstrating a direct relationship between
GCase and both GD and PD, coupled to its potential as a
therapeutic target, has raised high interest in developing
therapies that work to increase GCase activity in brain.
One technical challenge within the field is the lack of simple
and robust methods to assay GCase activity in tissue samples.
Measuring GCase activity in vitro generally relies on the use of
simple fluorogenic substrates such as resorufin β-D-glucopyr-
anoside (Res-Glc, Figure 1)11 or 4-methylumbelliferyl β-D-
glucopyranoside (4-MU-Glc).5,6,8,9 The presence of function-
ally related β-glucosidases which also cleave these substrates
including GBA212 (GH116) and GBA313 (GH1), however,
Received: December 28, 2019
Accepted: February 28, 2020
Published: February 28, 2020
Letterspubs.acs.org/acschemicalbiology
© XXXX American Chemical Society
A
https://dx.doi.org/10.1021/acschembio.9b01044













































































































complicates such assays. In efforts to circumvent this problem,
subtractive assays using inhibitors such as conduritol B epoxide
(CBE),5,8−10,14,15 which preferentially inactivates GCase over
GBA2 and GBA3, or miglustat, a GBA2-selective inhibitor,16
are commonly used. The more extensive manipulations
required in such assays coupled to the use of CBE, which
shows significant activity toward GBA2 at commonly used
concentrations (>1 mM),17 compromise the accuracy of these
measures.
The common use of such subtractive assays stems from a
lack of selective substrates for GCase over GBA2 and GBA3,
and whereas GCase is a prominent example, this shortage of
enzyme-selective substrates is, with few exceptions,18,19 a
problem that is common to most mammalian glycoside
hydrolases. Here we aimed to work toward addressing this
problem, focusing on generating a GCase-selective substrate
and illustrating its utility in assaying enzymatic activity within
brain tissue homogenates from transgenic model mice
expressing a clinically relevant mutant form of human GCase.
■ RESULTS AND DISCUSSION
In considering designs for selective substrates for GCase, we
were inspired by work from the Overkleeft group in which
cyclophellitol, a pan-selective covalent β-glucosidase inactiva-
tor, was made selective for GCase by appending a fluorophore
to the pseudo C-6 position.20 The tolerance of GCase for
modifications at the C-6 position was found to be a general
approach to confer selectivity, as shown in subsequent work
directed toward fluorescence-quenched substrates for this
enzyme.21 Whereas it is useful for imaging GCase activity in
cells, this fluorescence-quenched substrate is only slowly
processed by GCase and is poorly suited to analyze GCase
activity in biological fluids or tissue homogenates. Given these
considerations, we selected resorufin β-D-glucopyranoside as
the starting point for a selective substrate because it offers
several advantages over the more widely used 4-MU-Glc. In
particular, the low-pH optimum of GCase leaves resorufin (pKa
= 5.8) suitable for more precise continuous assays, whereas 4-
methylumbelliferone (4-MU, pKa = 7.8) requires the use of a
stopped assay in which base is used to terminate the enzymatic
reaction. Furthermore, resorufin was also attractive because the
red-shifted excitation and emission (Ex: 572 nm, Em: 583 nm)
helps to improve the sensitivity in cell lysates and tissue
homogenates by reducing the background signal due to
autofluorescence. We therefore designed and synthesized
(Supporting Information, Scheme S1) a small panel of C-6
triazole-modified analogues of resorufin β-D-glucopyranoside
(12−15), each having different hydrophobicities and steric
bulk (Figure 1).
We next assayed these candidate substrates with recombi-
nant GCase and counterassayed them with GBA2 and GBA3.
To our surprise, no enzymatic turnover was observed for any
of the substrates against any of these three enzymes. We
reasoned that C-6 modification in combination with the bulky
aryl group of resorufin was simply too sterically demanding for
the active site of GCase. We therefore decided to test whether
changing our C-6 conjugation strategy from a triazole linker to
a simple amide linker might reduce the steric congestion and
yield a viable GCase substrate. Unfortunately, after the
preparation of the C-6 acetamide (16; Scheme S1), we
Figure 1. Candidate GCase-selective substrates. GCase-catalyzed hydrolysis of Res-Glc fluorogenic substrates to liberate resorufin (boxed) and the
series of candidate GCase-selective substrates designed for synthesis and testing.
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found that it, too, was not turned over by GCase. We reasoned
that perhaps further reducing the steric bulk of the C-6 linker
by using a less demanding linker that also has more flexibility
could solve this problem.
We therefore prepared O-6 alkylated derivatives by
establishing a route that minimized the number of protecting
group manipulations and permitted the installation of a 4-
azidobutane group at this position using reductive alkylation
chemistry (Scheme 1). Using methyl α-D-glucopyranoside as a
starting material, selective protection using 4-chlorobutanal
dimethyl acetal afforded methyl 4,6-(4-chlorobutylidene)-α-D-
glucopyranoside (1). The reductive ring opening of (1)
repeatedly failed and required acetylation of the free hydroxyl
groups to generate di-O-acetyl (2) prior to ring opening using
AlCl3 and tetramethyl disiloxane (TMDS).
22 The desired 6-O-
chlorobutane (3) was the only regioisomer we observed.
Acetylation of the free hydroxyl to give tri-O-acetyl (4),
followed by acid-catalyzed hydrolysis and O-acetylation yielded
tetra-O-acetyl (5). Halide displacement provided azide (6).
The generation of the glycosyl bromide followed by the
subsequent phase transfer glycosylation yielded our common
intermediate resorufin 2,3,4-tri-O-acetyl-6-(4-azidobutane)-6-
deoxy-β-D-glucopyranoside (7). Using copper-catalyzed azide
alkyne cycloaddition (CuAAC) chemistry, we efficiently
obtained a series of per-O-acetylated O-6 modified glucosides,
which we deprotected using MeOH/K2CO3 to furnish the
target substrates (8−10). Likewise, compound 11 was
obtained by de-O-acetylation of compound 7 using MeOH/
K2CO3.
We were pleased to observe that GCase processed these
compounds and established Michaelis−Menten parameters for
each substrate (Table 1 and Figure S1). The large Km values of
substrates 8 and 10 made it impractical to achieve the
saturation of GCase, precluding the determination of complete
Michaelis−Menten parameters. We were, however, able to
determine kcat/Km values (Table 1) for all substrates, enabling
their direct comparison. The second-order rate constants for
these substrates were between 7 and 186% of the parent Res-
Glc substrate, and the kcat values were between 0.5 and 10
times higher than that measured for Res-Glc (Table 1). Having
established that these substrates are efficiently hydrolyzed by
GCase, we evaluated their selectivity with respect to GBA2 and
GBA3. There was negligible turnover of any of these O-6-
modified substrates by GBA2 (Table 2). This observation is
consistent with the recent X-ray crystal structure of a bacterial
homologue of GBA2, which reveals that the O-6 hydroxyl is
involved in forming critical binding interactions within the
active site.23 For GBA3, which is known to be a promiscuous
β-glucosidase,13 we observed the turnover of all substrates
tested (Table 2). To quantify the selectivity, we compared the
second-order rate constants obtained for each substrate with
these enzymes and observed selectivity ranging from 8- to 49-
fold for GCase over GBA3. Interestingly, the substrate
selectivity appeared to be largely independent of the steric
bulk because substrate 8, which simply bears a primary alcohol,
and the much larger cyclohexanol substrate 9 showed similar
second-order rate constants. The morpholine derivative 10,
which we term MorSel-X (morpholine-selective substrate 10),
which is positively charged at the pH of the assay, was most
selective (49-fold). We judged that the level of selectivity of
MorSel-X was adequate for the analysis of GCase in lysates,
particularly because GBA3 is mostly present in the liver,
kidney, intestine, and spleen,13,24 and set out to validate it as a
potential tool compound for studying GCase activity in tissues.
Given the high interest in studying the role of GCase in PD
and neuronopathic forms of GD, the ability to conveniently
monitor GCase activity in brain tissue lysates is of importance
to the field. To demonstrate the ability of MorSel-X (10) to
selectively measure GCase activity, we collected brain tissue
from a transgenic Gaucher’s mouse model (JAX no. 019106)25
in which mouse GBA is replaced by mutant human GBA that
expresses the D409V mutant form of human GCase, which has
greatly reduced activity. This mouse model has been reliably
used to study the relationship between GCase and PD and its
GCase activity is well characterized.26 We used MorSel-X and
contrasted it with the commonly used nonselective substrate
Scheme 1. Synthesis of Candidate O-6 Alkylated Res-Glc
GCase-Selective Substratesa
aReagents and conditions: (a) chlorobutyraldehyde dimethyl acetal,
CSA (cat.), 4 Å sieves, MeCN 70 °C, 70%; (b) Py., Ac2O, 0°C,
quant.; (c) TMDS, AlCl3, DCM, −78 to 0 °C, 66%; (d) Py., Ac2O, 0
°C, 93%; (e) H2SO4 (cat.), AcOH/Ac2O (1:1), 85%; (f) NaN3,
DMF, 70°C, 86%; (g) i, TMS-Br, ZnBr2, DCM 0 °C, ii, resorufin,
TBABr, NaOH, DCM/H2O (1:1), 24% over two steps; (h) i, alkyne,
sodium ascorbate, Cu(II)SO4, DCM/H2O (1:1), ii, K2CO3 (cat.),
MeOH, 24-57% over two steps; and (i) K2CO3 (cat.), MeOH., 82%.
Table 1. Michaelis−Menten Parameters for Turnover of






Res-Glc 29 ± 3 1.5 ± 0.1 31 120 ± 50
8 n.d. n.d. 3600 ± 100
9 200 ± 10 2.7 ± 0.1 16 600 ± 400
10, MorSel-X n.d. n.d. 6900 ± 200
11 260 ± 30 14 ± 1 58 000 ± 3000
an.d. = not determined
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Res-Glc by assaying β-glucosidase activity in brain tissue from
age-matched homozygous (D409V/D409V), heterozygous
(+/D409V), and wild type (WT) (+/+) mice having the
same genetic background (Figure 2). Using selective inhibitors
including AT3375 (Figure 2a), which is GCase-selective
(GCase IC50 = 43 nM, GBA2 IC50 = >100 μM, Figure S2),
and miglustat, a GBA2-selective inhibitor (GCase Ki = 685
μM, GBA2 Ki = 326 nM),
27 it was possible to parse out the
contribution of GCase, GBA2, and GBA3 to the observed
overall β-glucosidase activity. Using the nonselective Res-Glc
substrate, we found that the majority of β-glucosidase activity
in the mouse brain originates from GBA2, as the treatment
with AT3375 (10 μM) results in a modest reduction of only
39% in activity (Figure 2b). Likewise, treatment with miglustat
(10 μM) led to a 69% reduction in activity. Treatment with
both selective inhibitors, to enable the observation of GBA3
activity, led to background levels of signal, which is consistent
with the known absence of GBA3 in the brain based on the
expression profiling of GBA3.28 Using the current standard
subtractive approach, we measured GCase activities of 60 ±
1% for the heterozygote and 8.5 ± 0.3% for the homozygote.
We also assayed the homogenates using the more commonly
used fluorogenic substrate 4-methylumbelliferyl β-D-glucopyr-
anoside and closely recapitulated the literature values for
GCase activity in brain homogenate from D409V/D409V
mice, measuring 20.9 ± 0.6% as compared with the reported
literature value of 22 ± 4% (Figure S3). In contrast, we found
that when assaying homogenates treated with AT3375 (10
μM) using MorSel-X there was no detectable enzymatic
turnover (Figure 2c). This result demonstrated that the
selectivity we observed using recombinant enzymes translates
to selectivity in the more complex environment of brain
homogenates. Furthermore, the selectivity of MorSel-X for
GCase is independent of the presence of sodium deoxytaur-
ocholate (Figure S4), which has been shown to modulate
GCase and GBA2 activity.12 Interestingly, when we treated
homogenates with miglustat (10 μM), a 10−20% reduction in
activity as measured using MorSel-X was observed. We note
that Körschen et al. has reported similar levels of off-target
inhibition of GCase by miglustat in lysates,12 indicating that it
may have some limitations as an inhibitor tool compound and
further illustrating the complications associated with the
current subtractive assays.
We next used MorSel-X to measure the amount of residual
GCase activity in the mutant mouse lines as compared with the
WT mice. We measured 63 ± 3% residual GCase activity in
heterozygotes, which is in accord with literature reports,15 and
9 ± 3% in homozygotes. This latter value, in particular,
contrasts with reported values for residual GCase activity in
brain homogenates from D409V/D409V mice as compared
with homogenates from WT mice, which have been reported
as ranging from 19% to >30%.6,25,29 Interestingly, the 9 ± 3%
residual activity we measured is in direct agreement with
measurements of GCase activity in a wide range of other tissue
types including lung, liver, spleen, and fibroblasts from
D409V/D409V mice, where the measured activity ranges
from 2.5 ± 0.9% to 6 ± 3%.25 We speculated that reports on
the relatively high residual GCase activity in brains from
D409V/D409V mice as compared with WT mice stem from
inaccuracies arising due to the very high expression of GBA2 in
brain,12 which complicates the accurate measurements of low
levels of residual GCase activity in the brain that exacerbates
errors made when using subtractive assays with inhibitors.
To further test the utility of MorSel-X as a tool compound
for selectively monitoring GCase activity, we evaluated the
levels of GCase activity in GD patient fibroblasts. We assayed
Table 2. Comparison of the Second-Order Rate Constants for Processing of Candidate-Selective Substrates by Functionally
Related Human β-Glucosidases
substrate GCase kcat/Km (s
−1 M−1) GBA2 kcat/Km (s
−1 M−1)a GBA3 kcat/Km (s
−1 M−1) selectivity for GCase
8 3600 ± 100 3.8 ± 0.5 390 ± 60 9
9 16 600 ± 400 1700 ± 100 1710 ± 80 9
10, MorSel-X 6900 ± 200 n.d. 140 ± 50 49
11 58 000 ± 3000 110 ± 50 7100 ± 400 8
an.d. = not determined
Figure 2. Comparison of activity assay results obtained using Res-Glc with the subtractive β-glucosidase standard activity assay as compared with
those obtained using the selective GCase substrate MorSel-X. Analysis of tissue homogenates from mice (+/+, D409V/+, D409V/D409V) in the
presence of 0.16% (w/v) sodium deoxytaurocholate. Selective inhibitors miglustat and AT3375 were used to control for each of the human β-
glucosidases (AT3375 for GCase, miglustat for GBA2, and a combination of both for GBA3). (A) Structures of the selective iminosugar inhibitors
miglustat and AT3375. (B) Measurement of β-glucosidase activity in tissue homogenates using Res-Glc (100 μM). (C) Measurement of β-
glucosidase activity using MorSel-X (100 μM). Error bars represent SEM for the mean values obtained over three replicates of each of three
independent biological mouse brain samples for each of WT, heterozygote, and homozygote mice (n = 3 for each group).
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fibroblast lysates from a Gaucher’s patient (L444P/L444P,
GM01260) in the same way as the mouse brain homogenates
(Figure S5a). Notably, there is only low-level expression of
GBA2 in fibroblasts.12 The L444P mutation is particularly
deleterious, and the residual activity in this patient cell line is
reported to be 5%.30 When assaying lysates with MorSel-X, we
found a similarly low 2% residual activity (Figure S5b). This
concordance demonstrated the ability of MorSel-X to
accurately measure levels of residual GCase in patient cell lines.
In conclusion, O-alkylation of the O-6 position of Glc-Res
leads to fluorogenic substrates selective for GCase over GBA2
and GBA3. The nature of the pendent group allows tuning of
substrate selectivity, and we found that MorSel-X shows good
selectivity for GCase with a >100 times higher kcat/Km value as
compared with GBA2 and 49 times higher value as compared
with GBA3. This selectivity is preserved in more in complex
tissue samples such as the brain. Therefore, the application of
MorSel-X significantly simplifies the current approaches used
to measure the GCase activity and will facilitate research in the
field focused on advancing knowledge regarding GCase and
GCase-targeted therapeutics for PD and GD. Finally, we hope
that the general approach used here to realize selective
substrates for GCase also provides a framework for the pursuit
of selective substrates for other glycoside hydrolases as a means
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